The Basal Nucleus of Meynert (NBM) is a critical cholinergic nucleus in the basal forebrain that provides the primary source of acetylcholine to the cerebral cortex and hippocampus. Degeneration of NBM neurons is one of the earliest and most consistent pathological findings in Alzheimer's disease, making this nucleus central to understanding memory impairment and cognitive decline in neurodegeneration. [1]
The Basal Nucleus of Meynert is a major cholinergic nucleus in the basal forebrain, providing widespread cortical and hippocampal cholinergic innervation. [2]
| Property | Value | [3]
|----------|-------| [4]
| Category | Basal Forebrain Cholinergic |
| Location | Basal forebrain, substantia innominata, horizontal limb of diagonal band |
| Cell Types | Cholinergic projection neurons |
| Primary Neurotransmitter | Acetylcholine |
| Key Markers | ChAT (Choline Acetyltransferase), p75^NTR, TrkA |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000646 | basal cell |
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:0000646 | basal cell | Medium |
| Cell Ontology | CL:2000056 | Meynert cell | Medium |
The NBM is located in the basal forebrain, specifically in the:
NBM neurons project to virtually all regions of the cerebral cortex:
The NBM contains two main populations:
NBM cholinergic neurons are essential for cortical activation and cognitive function:
Acetylcholine release in cortex produces:
NBM neurons undergo severe and progressive degeneration in AD:
The cholinergic hypothesis of AD, proposed in the 1970s, remains relevant: "The loss of cholinergic neurons in the basal forebrain is a consistent feature of AD and contributes to memory impairment"
Cholinergic dysfunction contributes to PD symptoms:
Standard treatments for AD that enhance cholinergic transmission:
NBM degeneration can be assessed through:
PET Imaging: Cholinergic receptor ligands
CSF Markers: Choline acetyltransferase activity
MRI: Basal forebrain volume atrophy
Basal Forebrain
Cholinergic System
Cognitive Decline
The study of Basal Nucleus Of Meynert Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Mesulam M, et al. Cholinergic basal forebrain atrophy in AD. Neurology. 2020;95(12):e1663-e1673. 2020. ↩︎
Schliebs R, Arendt T. The significance of the cholinergic system in AD. J Neural Transm. 2011;118(4):573-597. 2011. ↩︎
Hampel H, et al. Cholinergic therapies for AD. Expert Opin Ther Targets. 2019;23(3):201-215. 2019. ↩︎
Bohnen NI, et al. Cholinergic PET imaging in neurodegenerative diseases. Mov Disord. 2022;37(1):44-55. 2022. ↩︎